146826
144953

Business  

Canopy Growth growing

Canopy Growth Corp. has signed a deal to buy a German company that specializes in cannabinoid-based medical therapies used by European physicians for roughly $342.9 million.

Under the deal, the Ontario-based company has acquired C3 Cannabinoid Compound Co.

C3's main medicinal offering is dronabinol, a compound with standardized concentrations of THC (tetrahydrocannabinol), the main psychoactive compound in cannabis.

Dronabinol is available in Austria, Denmark and Germany.

C3 has two manufacturing facilities specializing, respectively, in natural extraction and synthetic cannabinoid production.

The company's senior management team is expected to continue with the business.



More Business News

138937
147860
137176
Data from CryptoCompare
Recent Trending
144792
Soft 103.9
147026
Castanet Proud Member of RTNDA Canada
146622
Press Room
147112
146761